TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study of 116 adults found that slow brain waves during deep sleep became lower and flatter across groups ranging from cognitively unimpaired adults without abnormal amyloid biomarkers to people with early Alzheimer’s disease. Some differences in slow-wave power were present in cognitively unimpaired participants with abnormal amyloid biomarkers, but the findings do not establish a diagnostic test or show that sleep changes cause Alzheimer’s.
A study of 116 adults found that the shape and strength of brain waves during deep sleep differed across Alzheimer’s disease stages, with some changes appearing in cognitively unimpaired people who had abnormal amyloid biomarkers. Published in Alzheimer’s Research & Therapy, the findings suggest that sleep-wave patterns may help researchers study changes associated with Alzheimer’s before memory problems are apparent, but do not establish a screening test.
Researchers recorded one night of sleep using polysomnography at Hospital Clínic de Barcelona. Participants were divided into three groups: 30 cognitively unimpaired adults without abnormal amyloid biomarkers, 45 cognitively unimpaired adults with abnormal amyloid biomarkers, and 41 people with biomarker-confirmed mild cognitive impairment or mild dementia due to Alzheimer’s. About 57% were women, and group comparisons accounted for age and sex.
The clearest pattern was a progressive change in slow-wave shape. Average wave slope declined from about 370 microvolts per second in the amyloid-negative group to 342 in the amyloid-positive group and 300 among participants with early Alzheimer’s. The waves also became flatter and lower in amplitude across groups, according to the report. These measurements describe differences between study groups, not a threshold that can diagnose an individual.
Slow-wave power was also lower in the amyloid-positive group in two frequency bands, by about 13% to 15% compared with the amyloid-negative group. In early Alzheimer’s, power was about 15% to 21% lower than in the amyloid-negative group, depending on the band; delta power was also reduced. When researchers restricted an analysis to people who had slept at least six hours, the power difference between the two cognitively unimpaired groups was no longer statistically significant. The early Alzheimer’s group still showed lower delta and overall slow-wave activity power than the amyloid-negative group.
Broader sleep disruption was most apparent in the symptomatic group. Participants with early Alzheimer’s spent about 108 minutes awake after falling asleep, compared with roughly 61 to 64 minutes in the cognitively unimpaired groups. Their sleep efficiency was 69%, versus 79% to 83%, and they took about 157 minutes to reach REM sleep, compared with about 95 to 105 minutes. The two cognitively unimpaired groups did not differ significantly on these broad sleep measures.
The study also tracked cognition using a modified Preclinical Alzheimer’s Cognitive Composite over two to four visits across about six and a half years. The report describes the investigation as examining cognitive trajectories and sex differences, but the supplied results do not specify the detailed findings for those analyses or provide sex-specific estimates.
Deep Sleep as an Early Research Signal
The results add evidence that sleep recordings may capture differences associated with Alzheimer’s biology before cognitive symptoms are evident. The wave-shape pattern across the three groups is particularly relevant because it was observed along a continuum from amyloid-negative, cognitively unimpaired adults to people with early disease. That makes slow-wave features a possible subject for further biomarker research, rather than a confirmed way to predict who will develop symptoms.
Deep sleep, also called slow-wave sleep, is linked to memory consolidation. The report also describes prior research suggesting that the brain’s clearance of proteins including amyloid-beta and tau is enhanced during this stage. Those biological links offer a reason to study sleep in Alzheimer’s research, but this study does not show that disrupted sleep causes the disease or that changing sleep would prevent it.
For readers, the distinction between a group-level research finding and a clinical tool matters. The study used a single night of laboratory monitoring and a relatively small sample. Its measurements cannot, on their own, tell an individual whether they have Alzheimer’s disease or will develop it.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Bowflex SelectTech 840 Adjustable Kettlebell
Oura Ring 5 Smart Ring, Gold, Size 10
As an affiliate, we earn on qualifying purchases.
How Researchers Compared Sleep Stages
Alzheimer’s-related sleep research often distinguishes broad sleep patterns from the details of individual brain waves. The study measured both. Its sleep macroarchitecture measures included total sleep and time awake after sleep onset, while microarchitecture measures included slow-wave strength, slope, amplitude and duration.
The three groups were defined by cognitive status and amyloid biomarkers, which allowed the researchers to compare cognitively unimpaired adults with and without an Alzheimer’s-related biomarker against participants with symptomatic, biomarker-confirmed disease. The sample was enriched for Alzheimer’s risk factors: APOE-ε4 carriers made up 82.2% of the amyloid-positive group, compared with 40.0% of the amyloid-negative group and 48.8% of the early-disease group.
Participants did not have severe sleep apnea. Cognitively unimpaired participants were not taking sleep medication, while nine participants in the early Alzheimer’s group were. These details help describe the sample and are relevant when interpreting comparisons between groups.
“Slow-wave shape changes occur over the Alzheimer’s disease continuum and may represent non-invasive biomarkers for preclinical Alzheimer’s disease.”
— The study authors, as described in the News-Medical report
Limits of the Sleep-Wave Evidence
The study does not show whether the sleep-wave differences can reliably predict future Alzheimer’s symptoms in an individual. It compared groups at different points on the disease continuum, and the supplied report does not provide a validated cutoff, estimates of diagnostic accuracy, or evidence that the pattern is specific to Alzheimer’s rather than other influences on sleep or brain activity.
The findings also have limits tied to the sample and measurement. Each participant had one laboratory night of sleep monitoring, and the total sample was 116 people. The loss of statistical significance for the difference in slow-wave power between cognitively unimpaired groups after restricting the analysis to people who slept at least six hours adds uncertainty about how robust that early power difference is.
Although the study examined sex differences, the available account does not give the detailed results. It also does not establish whether sleep changes precede Alzheimer’s biology, result from it, or reflect a two-way relationship. The study reports associations, not cause and effect.
Validation Before Clinical Use
The reported findings point to a need for further research testing whether slow-wave shape measures are reproducible across nights and useful in larger, more diverse groups. Longitudinal studies would need to determine whether these patterns predict later cognitive change beyond existing clinical and biomarker information.
Researchers would also need to clarify how age, sex, medication, sleep duration and other sleep conditions affect the measurements, and to report the sex-specific results examined in this study. Until such work establishes performance and clinical value, deep-sleep wave analysis remains a research finding, not a diagnostic recommendation. The study report does not announce a next clinical milestone or a timeline for validation.
Key Questions
What did the study find about deep sleep?
It found that slow brain waves became progressively flatter and lower in amplitude across groups defined by amyloid biomarkers and Alzheimer’s disease status. Slow-wave power was also lower in some frequency bands in the amyloid-positive and early-disease groups.
Were changes found before memory symptoms?
Some differences, including reduced power in two bands and changes in wave shape, appeared in cognitively unimpaired participants with abnormal amyloid biomarkers. The study does not show that these changes predict when or whether an individual will develop symptoms.
Does this study provide a test for Alzheimer’s?
No. It reports group-level findings from one night of laboratory sleep monitoring. It does not establish a validated diagnostic test or provide a clinical cutoff for interpreting an individual’s sleep waves.
Did the researchers find that poor sleep causes Alzheimer’s?
No. The study found associations between sleep-wave features and Alzheimer’s-related groups. It cannot determine whether sleep changes cause disease, result from it, or are related in both directions.
What remains to be studied?
Researchers need to test whether the findings hold in larger samples, across multiple nights, and over time, and whether the measures can predict cognitive change. Detailed results on the study’s sex-difference analyses were not included in the available report.
Source: news-medical.net
